78156-39-5

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Bromo-5-methoxypyridine-1-oxide is utilized as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its presence in these industries is attributed to its potential role in creating new compounds with therapeutic or pesticidal properties.
Used in Organic Synthesis:
3-Bromo-5-methoxypyridine-1-oxide is employed as a key component in organic synthesis, where its unique structure and reactivity contribute to the formation of diverse chemical entities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-Bromo-5-methoxypyridine-1-oxide is used as a building block for the preparation of compounds with potential therapeutic applications. Its structural features allow for the development of new drugs with improved efficacy and selectivity.
Used in Material Science:
3-Bromo-5-methoxypyridine-1-oxide also finds applications in material science, where its properties can be harnessed to create new materials with specific characteristics for various applications.

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 
• 93-59-4 Perbenzoic acid 
• 67-56-1 methanol 
• 2402-99-5 3,5-dibromopyridine-N-oxide 
• 625-92-3 3,5-dibromopyridine 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 

Downstream Products

• 78156-40-8 3-amino-5-methoxypyridine N-oxide 
• 64436-92-6 3-amino-5-methoxypyridine 
• 42409-58-5 5-bromo-3-methoxy-pyridin-2-amine 
• 52605-98-8 5-bromo-2,3-dimethoxypyridine 
• 1253408-56-8 C₂₄H₂₈N₆O₄S 
• 1379325-16-2 3-bromo-5-methoxypyridin-2-amine 
• 1241752-31-7 2-ethoxy-3-methoxy-5-bromopyridine 
• 1581767-17-0 5-cyclohexyl-3-hydroxypyridin-2(1H)-one 
• 1581767-61-4 5-cyclohexenyl-2-ethoxy-3-methoxypyridine 
• 1581767-18-1 5-[3-(1H-tetrazol-5-yl)phenyl]-3-hydroxypyridin-2(1H)-one 
• 1333146-11-4 5-(m-cyanophenyl)-3-hydroxypyridin-2(1H)-one 
• 1454909-34-2 2,3-dimethoxy-5(3-cyanophenyl)pyridine 
• 1581767-04-5 6-bromo-5-(4-fluorophenyl)-3-hydroxypyridin-2(1H)-one 
• 1469896-37-4 2-ethoxy-3-methoxy-5-(4-fluorophenyl)pyridine 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES

The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

An efficient, regioselective amination of 3,5-disubstituted pyridine N-oxides using saccharin as an ammonium surrogate

A process for the regioselective amination of unsymmetrical 3,5-substituted pyridine N-oxides has been developed utilizing cheap, readily available saccharin as an ammonium surrogate. High conversions of the corresponding saccharin adducts have been achieved under mild reaction conditions. In situ deprotection under acidic conditions allows for a one-pot process to substituted aminopyridines. High regioselectivities were obtained from a variety of 3,5-disubstituted pyridine N-oxides.

Phenyl substituted 3-hydroxypyridin-2(1H)-ones: Inhibitors of influenza A endonuclease

Inhibition of the endonuclease activity of influenza RNA-dependent RNA polymerase is recognized as an attractive target for the development of new agents for the treatment of influenza infection. Our earlier study employing small molecule fragment screening using a high-resolution crystal form of pandemic 2009 H1N1 influenza A endonuclease domain (PAN) resulted in the identification of 5-chloro-3-hydroxypyridin-2(1H)-one as a bimetal chelating ligand at the active site of the enzyme. In the present study, several phenyl substituted 3-hydroxypyridin-2(1H)-one compounds were synthesized and evaluated for their ability to inhibit the endonuclease activity as measured by a high-throughput fluorescence assay. Two of the more potent compounds in this series, 16 and 18, had IC50 values of 11 and 23 nM in the enzymatic assay, respectively. Crystal structures revealed that these compounds had distinct binding modes that chelate the two active site metal ions (M1 and M2) using only two chelating groups. The SAR and the binding mode of these 3-hydroxypyridin-2-ones provide a basis for developing a new class of anti-influenza drugs.

UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY

Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.

An efficient large-scale synthesis of alkyl 5-hydroxy-pyridin- and pyrimidin-2-yl acetate

The synthesis of methyl 2-(5-hydroxy-3-methoxypyridin-2-yl)acetate and alkyl 2-(5-hydroxypyrimidin-2-yl)acetate is described. Methodology for an efficient access to 5-hydroxy-pyridin- and pyrimidin-2-yl acetate cores has been developed. Based on the difference in halogen reactivity, 5-bromo-2-chloropyridine and its pyrimidine analogue were functionalized judiciously by SNAr and palladium-catalyzed reactions. The outlined strategy provides a high-yielding route suitable for large-scale synthesis of these compounds as well as paves the way for a potential rapid access to other heterocyclic analogues.

STUDIES ON 3,5-DIOXOPIPERIDINES: NOVEL AND FACILE SYNTHETIC ROUTES TO 3-AMINO-5-HYDROXYPYRIDINE DERIVATIVES

Three novel synthetic routes to the title compounds were described.Modified Polonovski reaction of 3-acetamido-1-benzyl-5-oxo-3,4-dehydropiperidine (4) or Semmler-Wolff aromatization of 1-benzyl-3-methoxy-5-oxo-3,4-dehydropiperidine oxime (9) followed by reductive debenzylations gave 3-acetamido-5-hydroxypyridine (6) or 3-acetamido-5-methoxypyridine (11), respectively.Nucleophilic replacement of 3,5-dibromopyridine N-oxide (13) with methoxy and amino groups followed by deoxygenation gave 3-amino-5-methoxypyridine (12).